Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024
Get in-depth analysis of the COVID-19 impact on the Vaccines Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Vaccines Market
Request For Special Pricing[188 Pages Report] The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The growth of this market is majorly attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.
Pediatric patients segment accounted for the larger share of the vaccines market, by patient type.
On the basis of patient type, the vaccines market is segmented into pediatric and adult patients. The pediatric patients segment accounted for the largest share of the global vaccines market in 2018. This can be attributed to the increasing government initiatives for immunization and the rising prevalence of diseases.
By technology, the conjugate vaccines segment accounted for the largest market share in 2018.
On the basis of technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate vaccines segment accounted for the largest share of the vaccines market. The large share of this segment can be attributed to increasing government support and rising company investments in conjugate vaccine development.
Intramuscular & subcutaneous administration segment to witness the highest growth during the forecast period
On the basis of the route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment accounted for the largest share of the global vaccines market in 2018 and is projected to register the highest CAGR during the forecast period. This mode of administration is associated with better immune response and a lower rate of injection site reactions.
North America dominates the vaccines market
North America accounted for the largest share of the vaccines market in 2018. The large share of North America in the global vaccines market is attributed to the high prevalence of infectious diseases and increasing investments by government and non-government organizations for vaccine development. The market in Asia, on the other hand, is projected to register the highest growth during the forecast period. Factors such as the increasing healthcare expenditure and increasing disposable income, government initiatives, and the presence of a large patient population are driving the growth of the vaccines market in Asia.
Key Market Players
The major players in the global vaccines market are GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), and Sanofi Pasteur SA (France). Other prominent players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), Serum Institute of India (India), AstraZeneca (UK), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).
Scope of the Report:
|
Report Metric |
Details |
|
Market size available for years |
20172024 |
|
Base year considered |
2018 |
|
Forecast period |
20192024 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Technology, type, disease indication, route of administration, patient type, and region |
|
Geographies covered |
North America, Europe, Asia, and the Rest of the World |
|
Companies covered |
GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), Merck & Co., Inc. (US), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd. (China), Incepta Vaccine Ltd. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and PT Bio Farma (Brazil). |
The research report categorizes the vaccines market into the following segments and subsegments:
- Technology
- Conjugate vaccines
- Inactivated and subunit vaccines
- Live attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Type
- Monovalent vaccines
- Multivalent vaccines
- Disease Indication
- Pneumococcal disease
- DTP
- Influenza
- HPV
- Meningococcal disease
- Polio
- Rotavirus
- Hepatitis
- MMR
- Varicella
- Herpes zoster
- Other disease indications
- Route of Administration
- Intramuscular and subcutaneous administration
- Oral administration
- Other routes of administration
- Patient Type
- Pediatric patients
- Adult patients
- Region
- North America
- Europe
- Asia
- Rest of the World
Critical questions answered in the report:
- How will the current technological trends affect the vaccines market in the long term?
- What are the reasons contributing to the growth of the conjugate vaccines segment in the market?
- Which regions are likely to grow at the highest CAGR?
- What are the challenges hindering the adoption of vaccines?
- What are the growth strategies being implemented by major market players?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 22)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Share Analysis
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 28)
4 Premium Insights (Page No. - 32)
4.1 Vaccines Market Overview
4.2 North America: Vaccines Market, By Technology (2018)
4.3 Geographical Snapshot of the Vaccines Market
5 Market Overview (Page No. - 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.5 Burning Issues
5.2.5.1 Product Recalls
6 Industry Insights (Page No. - 42)
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 HIV
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding
6.3.4.4 Ebola projects funded by EC (20142020)
7 Vaccines Market, By Technology (Page No. - 56)
7.1 Introduction
7.2 Conjugate Vaccines
7.2.1 Conjugate Vaccines Hold the Largest Share of the Market
7.3 Inactivated & Subunit Vaccines
7.3.1 Ease of Storage and Transportation have Made Inactivated & Subunit Vaccines Popular
7.4 Live Attenuated Vaccines
7.4.1 Issues in Preserving and Maintaining Live Attenuated Vaccines has Slowed Market Growth
7.5 Recombinant Vaccines
7.5.1 Lack of Post-Vaccination Reactions and Reduced Need for Booster Doses are Driving R&D Into Recombinant Vaccines
7.6 Toxoid Vaccines
7.6.1 Company Initiatives and the Introduction of New Vaccines Will Support Market Growth
8 Vaccines Market, By Type (Page No. - 64)
8.1 Introduction
8.2 Monovalent Vaccines
8.2.1 in 2018, the Monovalent Vaccines Segment Accounted for the Largest Share of the Market
8.3 Multivalent Vaccines
8.3.1 Increasing Initiatives By Companies to Develop New Multivalent Vaccines is Driving the Growth of This Segment
9 Vaccines Market, By Disease Indication (Page No. - 68)
9.1 Introduction
9.2 Pneumococcal Disease
9.2.1 Pneumococcal Disease Segment Accounted for the Largest Share of the Market
9.3 DTP
9.3.1 Increasing Accessibility of DTP Vaccines in Developing Countries to Drive Market Growth
9.4 Influenza
9.4.1 Influenza Vaccines Segment to Grow at the Highest Rate During the Forecast Period
9.5 HPV
9.5.1 Growing Prevalence of HPV Infections to Support Market Growth
9.6 Meningococcal Disease
9.6.1 Rising Incidence of Meningococcal Disease to Support the Growth of This Market Segment
9.7 Polio
9.7.1 Government Initiatives to Support the Growth of This Market Segment
9.8 Hepatitis
9.8.1 High Prevalence of Hepatitis Infections is Driving the Demand for Immunization
9.9 Rotavirus
9.9.1 Rising Incidence of Rotavirus Infections to Drive Market Growth
9.10 MMR
9.10.1 Rising Incidence of Measles, Mumps, and Rubella Will Support the Growth of This Market Segment
9.11 Varicella
9.11.1 Promotion of Immunization Programs to Drive the Demand for Varicella Vaccines
9.12 Herpes Zoster
9.12.1 Herpes Zoster Vaccines to Witness Stable Demand During the Forecast Period
9.13 Other Disease Indications
10 Vaccines Market, By Route of Administration (Page No. - 85)
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.2.1 Intramuscular and Subcutaneous Administration Accounted for the Largest Share of the Market
10.3 Oral Administration
10.3.1 Possibility of Irritation of the Gastric Mucosa May Limit the Growth of This Segment
10.4 Other Routes of Administration
11 Vaccines Market, By Patient Type (Page No. - 90)
11.1 Introduction
11.2 Pediatric Patients
11.2.1 In 2018, the Pediatric Patients Segment Accounted for the Largest Share of the Market
11.3 Adult Patients
11.3.1 The Adult Patients Segment is Expected to Grow at the Highest CAGR During the Forecast Period
12 Vaccines Market, By Region (Page No. - 94)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.1.1 The US is the Largest Market for Vaccines
12.2.2 Canada
12.2.2.1 High Incidence of Infectious Diseases is Driving the Demand for Vaccines in the Country
12.3 Europe
12.3.1 Germany
12.3.1.1 Significant Investments in R&D to Support Market Growth
12.3.2 UK
12.3.2.1 Launch of New Products to Support Market Growth in the UK in the Coming Years
12.3.3 France
12.3.3.1 Favorable Government Initiatives for Immunization to Support Market Growth in France
12.3.4 Italy
12.3.4.1 Conjugate Vaccines to Account for the Largest Share of the Italian Market
12.3.5 Spain
12.3.5.1 Rising Investments in Vaccine Development By Private Organizations to Support Market Growth in Spain
12.3.6 Rest of Europe
12.4 Asia
12.4.1 Japan
12.4.1.1 Government Initiatives for Increasing the Accessibility of Vaccines to Drive Market Growth in Japan
12.4.2 China
12.4.2.1 Growing Investments in the Biotechnology Sector to Drive Market Growth in China
12.4.3 India
12.4.3.1 Growth of the Biotechnology Sector and Development of New Vaccines to Support Market Growth in India
12.4.4 Rest of Asia
12.5 Rest of the World
12.5.1 Latin America
12.5.2 Other RoW Countries
13 Competitive Landscape (Page No. - 125)
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Leadership Mapping (Overall Market)
13.3.1 Visionary Leaders
13.3.2 Innovators
13.3.3 Dynamic Differentiators
13.3.4 Emerging Companies
13.4 Competitive Situation and Trends
13.4.1 Agreements, Contracts, and Collaborations
13.4.2 Product Launches and Approvals
13.4.3 Acquisitions
13.4.4 Expansions
14 Company Profiles (Page No. - 132)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
14.1 Glaxosmithkline PLC
14.2 Pfizer, Inc
14.3 Merck & Co., Inc
14.4 Sanofi Pasteur SA
14.5 CSL Limited
14.6 Emergent Biosolutions, Inc
14.7 Johnson & Johnson
14.8 Astrazeneca
14.9 Serum Institute of India Pvt., LTD
14.10 Bavarian Nordic
14.11 Mitsubishi Tanabe Pharma Corporation
14.12 Daiichi Sankyo Company, Limited
14.13 Panacea Biotec, LTD
14.14 Biological E
14.15 Bharat Biotech
14.16 Other Companies
14.16.1 Sinovac Biotech, LTD
14.16.2 Incepta Vaccine, LTD
14.16.3 Valneva SE
14.16.4 VBI Vaccines Inc
14.16.5 PT Bio Farma (Persero)
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
15 Appendix (Page No. - 179)
15.1 Discussion Guide
15.2 Knowledge Store: Marketsandmarkets Subscription Portal
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details
List of Tables (107 Tables)
Table 1 Incidence of Infectious Diseases
Table 2 NIH Funding for Vaccine Research, 20132018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2016 vs 2018
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Vaccines Market, By Technology, 20172024 (USD Million)
Table 8 Cost of Meningococcal Conjugate Vaccines for Pediatric Patients
Table 9 Cost of Meningococcal Conjugate Vaccines for Adult Patients
Table 10 Conjugate Vaccines Market, By Region, 20172024 (USD Million)
Table 11 Examples of Inactivated & Subunit Vaccines
Table 12 Inactivated & Subunit Vaccines Market, By Region, 20172024 (USD Million)
Table 13 Live Attenuated Vaccines Market, By Region, 20172024 (USD Million)
Table 14 Examples of Recombinant Vaccines
Table 15 Recombinant Vaccines Market, By Region, 20172024 (USD Million)
Table 16 Toxoid Vaccines Market, By Region, 20172024 (USD Million)
Table 17 Vaccines Market, By Type, 20172024 (USD Million)
Table 18 Monovalent Vaccines Market, By Region, 20172024 (USD Million)
Table 19 Examples of Notable Multivalent Vaccines Available in the Market
Table 20 Multivalent Vaccines Market, By Region, 20172024 (USD Million)
Table 21 Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 22 List of Commercially Available Pneumococcal Vaccines in the Market
Table 23 Vaccines Market for Pneumococcal Disease, By Region, 20172024 (USD Million)
Table 24 List of Commercially Available DTP Vaccines in the Market
Table 25 Vaccines Market for DTP, By Region, 20172024 (USD Million)
Table 26 List of Commercially Available Influenza Vaccines in the Market
Table 27 Vaccines Market for Influenza, By Region, 20172024 (USD Million)
Table 28 List of Commercially Available HPV Vaccines in the Market
Table 29 Vaccines Market for HPV, By Region, 20172024 (USD Million)
Table 30 List of Commercially Available Meningococcal Disease Vaccines in the Market
Table 31 Vaccines Market for Meningococcal Disease, By Region, 20172024 (USD Million)
Table 32 List of Commercially Available Polio Vaccines in the Market
Table 33 Vaccines Market for Polio, By Region, 20172024 (USD Million)
Table 34 List of Commercially Available Hepatitis Vaccines in the Market
Table 35 Vaccines Market for Hepatitis, By Region, 20172024 (USD Million)
Table 36 List of Commercially Available Rotavirus Vaccines in the Market
Table 37 Vaccines Market for Rotavirus, By Region, 20172024 (USD Million)
Table 38 List of Commercially Available MMR Vaccines in the Market
Table 39 Vaccines Market for MMR, By Region, 20172024 (USD Million)
Table 40 List of Commercially Available Varicella Vaccines in the Market
Table 41 Vaccines Market for Varicella, By Region, 20172024 (USD Million)
Table 42 Vaccines Market for Herpes Zoster, By Region, 20172024 (USD Million)
Table 43 List of Commercially Available Vaccines for Other Disease Indications
Table 44 Vaccines Market for Other Disease Indications, By Region, 20172024 (USD Million)
Table 45 Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 46 Advantages and Disadvantages of Intramuscular and Subcutaneous Administration
Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 20172024 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 20172024 (USD Million)
Table 49 Vaccines Market for Other Routes of Administration, By Region, 20172024 (USD Million)
Table 50 Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 20172024 (USD Million)
Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 20172024 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 20172024 (USD Million)
Table 54 North America: Vaccines Market for Adult Patients, By Country, 20172024 (USD Million)
Table 55 Vaccines Market, By Region, 20172024 (USD Million)
Table 56 North America: Vaccines Market, By Country, 20172024 (USD Million)
Table 57 North America: Vaccines Market, By Technology, 20172024 (USD Million)
Table 58 North America: Vaccines Market, By Type, 20172024 (USD Million)
Table 59 North America: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 60 North America: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 61 North America: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 62 Number of New Infectious Disease Cases in the Us, 2017
Table 63 US: Vaccines Market, By Technology, 20172024 (USD Million)
Table 64 US: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 65 Number of New Infectious Disease Cases in Canada
Table 66 Canada: Vaccines Market, By Technology, 20172024 (USD Million)
Table 67 Canada: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 68 Europe: Vaccines Market, By Country, 20172024 (USD Million)
Table 69 Europe: Vaccines Market, By Technology, 20172024 (USD Million)
Table 70 Europe: Vaccines Market, By Type, 20172024 (USD Million)
Table 71 Europe: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 72 Europe: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 73 Europe: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 74 Germany: Vaccines Market, By Technology, 20172024 (USD Million)
Table 75 UK: Vaccines Market, By Technology, 20172024 (USD Million)
Table 76 France: Vaccines Market, By Technology, 20172024 (USD Million)
Table 77 Italy: Vaccines Market, By Technology, 20172024 (USD Million)
Table 78 Spain: Vaccines Market, By Technology, 20172024 (USD Million)
Table 79 RoE: Vaccines Market, By Technology, 20172024 (USD Million)
Table 80 Asia: Health Expenditure Per Capita, By Country, 2000, 2014, and 2016 (USD)
Table 81 Asia: Vaccines Market, By Country, 20172024 (USD Million)
Table 82 Asia: Vaccines Market, By Technology, 20172024 (USD Million)
Table 83 Asia: Vaccines Market, By Type, 20172024 (USD Million)
Table 84 Asia: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 85 Asia: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 86 Asia: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 87 Disease Incidence in Japan, 20162018
Table 88 Japan: Vaccines Market, By Technology, 20172024 (USD Million)
Table 89 China: Vaccines Market, By Technology, 20172024 (USD Million)
Table 90 India: Vaccines Market, By Technology, 20172024 (USD Million)
Table 91 RoA: Vaccines Market, By Technology, 20172024 (USD Million)
Table 92 RoW: Vaccines Market, By Region, 20172024 (USD Million)
Table 93 RoW: Vaccines Market, By Technology, 20172024 (USD Million)
Table 94 RoW: Vaccines Market, By Type, 20172024 (USD Million)
Table 95 RoW: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 96 RoW: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 97 RoW: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 98 Latin America: Vaccines Market, By Technology, 20172024 (USD Million)
Table 99 Latin America: Vaccines Market, By Type, 20172024 (USD Million)
Table 100 Latin America: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 101 Latin America: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 102 Latin America: Vaccines Market, By Patient Type, 20172024 (USD Million)
Table 103 Other RoW Countries: Vaccines Market, By Technology, 20172024 (USD Million)
Table 104 Other RoW Countries: Vaccines Market, By Type, 20172024 (USD Million)
Table 105 Other RoW Countries: Vaccines Market, By Disease Indication, 20172024 (USD Million)
Table 106 Other RoW Countries: Vaccines Market, By Route of Administration, 20172024 (USD Million)
Table 107 Other RoW Countries: Vaccines Market, By Patient Type, 20172024 (USD Million)
List of Figures (35 Figures)
Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Vaccines Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Vaccines Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Vaccines Market, By Disease Indication, 2019 vs 2024 (USD Million)
Figure 10 Vaccines Market, By Route of Administration, 2019 vs 2024 (USD Million)
Figure 11 Vaccines Market, By Patient Type, 2019 vs 2024 (USD Million)
Figure 12 Geographical Snapshot of the Vaccines Market
Figure 13 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 14 Conjugate Vaccines Accounted for the Largest Share of the North American Vaccines Market in 2018
Figure 15 Asia to Witness the Highest Growth in the Vaccines Market From 2019 to 2024
Figure 16 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Regulatory Approval Process for Vaccines
Figure 18 North America Will Continue to Dominate the Vaccines Market in 2024
Figure 19 North America: Vaccines Market Snapshot
Figure 20 Europe: Vaccines Market Snapshot
Figure 21 Asia: Vaccines Market Snapshot
Figure 22 Vaccines Market Share Analysis, By Key Player, 2018 127
Figure 23 Competitive Leadership Mapping: Vaccines Market 130
Figure 24 Glaxosmithkline PLC.: Company Snapshot (2018)
Figure 25 Pfizer, Inc.: Company Snapshot (2018)
Figure 26 Merck & Co., Inc.: Company Snapshot (2018)
Figure 27 Sanofi Pasteur SA: Company Snapshot (2018)
Figure 28 CSL Limited: Company Snapshot (2018)
Figure 29 Emergent Biosolutions, Inc.: Company Snapshot (2018)
Figure 30 Johnson & Johnson: Company Snapshot (2018)
Figure 31 Astrazeneca: Company Snapshot (2018)
Figure 32 Bavarian Nordic: Company Snapshot (2018)
Figure 33 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2018)
Figure 34 Daiichi Sankyo Company: Company Snapshot (2018)
Figure 35 Panacea Biotec: Company Snapshot (2018)
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the vaccines market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the vaccines market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, type, disease indication, route of administration, patient type, and region).
Data Triangulation
After arriving at the market size, the vaccines market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments.
Objectives of the Study
- To define, describe, and forecast the global vaccines market by technology, type, disease indication, route of administration, patient type, and region
- To provide detailed information about the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the vaccines market in four major regions along with their respective key countries (North America, Europe, Asia, and the Rest of the World)
- To profile the key players in the global vaccines market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as product launches, expansions, and R&D activities of the leading players in the vaccines market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the vaccines market into South Korea, New Zealand, and other Southeast Asian countries
- Further breakdown of the European vaccines market into Belgium, the Netherlands, and Sweden
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Vaccines Market